August 19, 2020

HTA Quarterly Fall 2020 | Heard on the Street

By Amerisourcebergen

Syringe and vial The first batches of COVID-19 vaccines should go to “people most at risk of infection,” such as medical staff on the front lines or transport sector workers, not just in all EU countries, but internationally. But “we [countries] shouldn't fight each other. We should make it available community-wise, not country-wise ... I feel strongly about this,” said Guido Rasi, head of the European Medicines Agency (EMA), speaking on the importance of a global, coordinated approach to vaccine deployment.

The World Health Organization is tracking 26 candidate vaccines in clinical evaluation and 139 candidate vaccines in preclinical evaluation. Recent price and volume agreements include:

Pfizer/BioNTech:

Prices vaccine for the US at approximately $20/dose as the US government signs agreement to pay for $1.95 billion upon receipt of the first 100 million doses.
UK agrees to buy 30 million doses, and upon approval, Japan would be provided 120 million vaccine doses (pricing and details not given).

Sanofi/GlaxoSmithKline:

Prices vaccine for the US at approximately $21/dose as the US government signs agreement to pay $2.1 billion for 100 million doses and the ability to purchase up to 500 million doses over time.
UK government secured up to 60 million doses of an experimental treatment being developed.

AstraZenca/Oxford University:

UK signs deal to purchase 100 million doses.
One dose would cost around 2.5 euros in Europe, according to Italy’s health ministry. Cost in other regions not determined.

Moderna:

Announced pricing between $32 to $37 per course of vaccine to small purchasers with intent to ensure broad access.
Announced receiving a $472 million Biomedical Advanced Research and Development Authority (BARDA) grant to run its phase 3 COVID-19 trial.
The new funds in addition to the $483 million previously granted brings its total BARDA funding close to $1 billion.
Agreed to deliver 100 million doses to the US government in a deal worth $1.525 billion, which results in pricing of just under $25 per dose.

Valneva:

UK agrees to buy 60 million doses; pricing not disclosed.

Novovax:

US Department of Health and Human Services (HHS) and Department of Defense announced a $1.6 billion agreement with Novovax which would give the federal government 100 million doses if the vaccine comes to market.
UK agrees to buy 60 million doses, pricing not disclosed.

Johnson & Johnson:

Prices vaccine for the US at $10 per dose pricing for 100 million doses per agreement with government, with the option to order an additional 200 million doses.
Collaborated with BARDA for 1$ billion in funding of the vaccine.
Estimated cost of 10 euros per dose (stated in April). Pledged for no profit gain.
On August 13th, the company disclosed it is in talks to supply 200 million doses to the EU with the option to deliver an additional 200 million doses.

Sources:

HTA Quarterly Fall 2020 | Heard on the Street

Related Content

AmerisourceBergen は Cencora になりました

日本のヘルスケアロジスティクスの未来：国内航空輸送が変える、これからの患者ケア

AmerisourceBergenは、2023年よりCencora に変わります。